Breaking News Instant updates and real-time market news.

ALDR

Alder Biopharmaceuticals

$11.50

0.07 (0.61%)

08:14
07/11/19
07/11
08:14
07/11/19
08:14

Alder presents data on eptinezumab's efficacy in reducing migraine severity

The company said, "A second post-hoc analysis examined eptinezumab's efficacy in reducing migraine severity, which is a significant contributor to reduced quality of life and increased burden of disease. In the PROMISE-2 trial for chronic migraine, impact scores as measured by the Headache Impact Test were significantly elevated at baseline. The analysis, conducted within PROMISE-2, evaluated the efficacy and related functional and health-related quality of life outcomes of eptinezumab in those patients enrolled in the trial who, during a screening, reported very often or always experiencing severe headaches per HIT-6. Efficacy endpoints that were evaluated included: change from baseline in HIT-6 total score and frequency of severe pain during headaches, as well as change from baseline in the 36-item Short-Form Health Survey which is a general measure of health-related quality of life. Highlights include: Over half of eptinezumab-treated patients experienced greater than or equal toone-category decrease in the frequency of severe headaches by Month 1, compared to 43.7% for placebo. The decrease for patients treated with eptinezumab or placebo remained relatively consistent through the six-month study period. Eptinezumab treatment resulted in clinically meaningful improvements in HIT-6 scores as early as Month 1 after treatment, which were maintained or further improved throughout the six-month study period, compared to placebo, which did not achieve a clinically meaningful improvement until Month 6. In addition, eptinezumab treatment resulted in clinically meaningful improvements greater than placebo in SF-36 scores as early as Month 1 after treatment and through the six-month study period."

  • 09

    Sep

  • 21

    Feb

ALDR Alder Biopharmaceuticals
$11.50

0.07 (0.61%)

04/04/19
PIPR
04/04/19
NO CHANGE
PIPR
Overweight
Piper Jaffray stays Overweight on Alder Biopharma, Amgen after Novartis filing
Piper Jaffray analyst Christopher Raymond maintains his Overweight rating on Alder Biopharma (ALDR) and Amgen (AMGN) after the filing by Novartis (NVS) alleging legal dispute with the latter about their migraine collaboration. The analyst says that Novartis tried to beat Amgen to the punch after entering agreement with Alder to manufacture eptinezumab, which prompted Amgen to terminate their commercialization agreement. Raymond adds that a resolution of this dispute could take a year or more but believes that investors may conclude that the spat reflects the value of anti-CGRP assets.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
05/28/19
LEER
05/28/19
INITIATION
Target $21
LEER
Outperform
Alder Biopharmaceuticals initiated with an Outperform at SVB Leerink
SVB Leerink analyst Marc Goodman initiated Alder Biopharmaceuticals with an Outperform and $21 price target.
07/10/19
FBCO
07/10/19
INITIATION
Target $14
FBCO
Neutral
Alder Biopharmaceuticals assumed with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman assumed coverage of Alder Biopharmaceuticals with a Neutral rating and $14 price target.

TODAY'S FREE FLY STORIES

INAP

Internap

$2.76

-0.23 (-7.69%)

07:21
07/23/19
07/23
07:21
07/23/19
07:21
Hot Stocks
Internap launches Intelligent Monitoring managed cloud and monitoring service »

Internap Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLAB

Silicon Labs

$105.16

1.14 (1.10%)

07:21
07/23/19
07/23
07:21
07/23/19
07:21
Initiation
Silicon Labs initiated  »

Silicon Labs initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 13

    Sep

VIVE

Viveve

$0.41

-0.0155 (-3.68%)

07:21
07/23/19
07/23
07:21
07/23/19
07:21
Downgrade
Viveve rating change  »

Mizuho double downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$54.64

-0.25 (-0.46%)

07:20
07/23/19
07/23
07:20
07/23/19
07:20
Recommendations
Mondelez analyst commentary  »

Mondelez price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

INTC

Intel

$51.36

1.1 (2.19%)

07:19
07/23/19
07/23
07:19
07/23/19
07:19
Initiation
Intel initiated  »

Intel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 03

    Aug

TORC

ResTORbio

$11.18

1.15 (11.47%)

07:19
07/23/19
07/23
07:19
07/23/19
07:19
Hot Stocks
ResTORbio completes patient enrollment of Phase 3 PROTECTOR 1 trial »

resTORbio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$264.15

-14.91 (-5.34%)

07:18
07/23/19
07/23
07:18
07/23/19
07:18
Recommendations
Lennox analyst commentary  »

Lennox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

AGTC

Applied Genetic

$3.89

0.02 (0.52%)

07:18
07/23/19
07/23
07:18
07/23/19
07:18
Hot Stocks
Applied Genetic completes enrollment of third group in Phase 1/2 clinical study »

Applied Genetic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

PEBO

Peoples Bancorp

$31.80

0.08 (0.25%)

07:18
07/23/19
07/23
07:18
07/23/19
07:18
Earnings
Peoples Bancorp reports Q2 EPS 46c with items, consensus 68c »

Reports Q2 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

VIVE

Viveve

$0.41

-0.0155 (-3.68%)

07:16
07/23/19
07/23
07:16
07/23/19
07:16
Downgrade
Viveve rating change  »

Viveve downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$53.30

0.005 (0.01%)

07:16
07/23/19
07/23
07:16
07/23/19
07:16
Earnings
Rogers Communications reports Q2 adjusted EPS C$1.16 vs. C$1.07 last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

JBT

John Bean Technologies

$121.10

-0.995 (-0.81%)

07:16
07/23/19
07/23
07:16
07/23/19
07:16
Recommendations
John Bean Technologies analyst commentary  »

John Bean Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 19

    Sep

IEX

IDEX Corp.

$164.74

0.31 (0.19%)

07:15
07/23/19
07/23
07:15
07/23/19
07:15
Recommendations
IDEX Corp. analyst commentary  »

IDEX Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ROP

Roper Technologies

07:14
07/23/19
07/23
07:14
07/23/19
07:14
Recommendations
Roper Technologies analyst commentary  »

Roper Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

ACAD

Acadia

$25.97

0.28 (1.09%)

07:14
07/23/19
07/23
07:14
07/23/19
07:14
Recommendations
Acadia analyst commentary  »

Cantor sees failed trial,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 20

    Aug

PTI

Proteostasis

$0.89

-0.0209 (-2.31%)

, GLPG

Galapagos

$187.55

4.1 (2.23%)

07:14
07/23/19
07/23
07:14
07/23/19
07:14
Hot Stocks
Proteostasis appoints Geoffrey Gilmartin as Chief Medical Officer »

Proteostasis Therapeutics…

PTI

Proteostasis

$0.89

-0.0209 (-2.31%)

GLPG

Galapagos

$187.55

4.1 (2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 09

    Sep

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:14
07/23/19
07/23
07:14
07/23/19
07:14
Earnings
RedHill Biopharma reports Q2 EPS (4c), consensus (35c) »

Reports Q2 revenue $1.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

XLNX

Xilinx

$124.24

1.52 (1.24%)

07:12
07/23/19
07/23
07:12
07/23/19
07:12
Initiation
Xilinx initiated  »

Xilinx initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 08

    Aug

FB

Facebook

$202.32

3.94 (1.99%)

07:12
07/23/19
07/23
07:12
07/23/19
07:12
Recommendations
Facebook analyst commentary  »

Facebook price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CCBG

Capital City Bank

$24.70

0.11 (0.45%)

07:11
07/23/19
07/23
07:11
07/23/19
07:11
Earnings
Capital City Bank reports Q2 EPS 44c, consensus 42c »

"I am very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$207.21

4.59 (2.27%)

07:10
07/23/19
07/23
07:10
07/23/19
07:10
Recommendations
Apple analyst commentary  »

KeyBanc sees little to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 03

    Aug

MBIO

Mustang Bio

$3.09

-0.16 (-4.92%)

07:10
07/23/19
07/23
07:10
07/23/19
07:10
Hot Stocks
Mustang Bio treatment of acute myeloid leukemia granted FDA orphan status »

Mustang Bio's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUGRY

United Utilities

$0.00

(0.00%)

07:09
07/23/19
07/23
07:09
07/23/19
07:09
Upgrade
United Utilities rating change  »

United Utilities upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LJPC

La Jolla

$8.54

-0.16 (-1.84%)

07:09
07/23/19
07/23
07:09
07/23/19
07:09
Hot Stocks
La Jolla treatment of malaria granted FDA orphan status »

La Jolla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPG

Interpublic Group

$22.78

-0.01 (-0.04%)

07:09
07/23/19
07/23
07:09
07/23/19
07:09
Hot Stocks
Interpublic Group remains on track to deliver 2%-3% organic growth »

Michael Roth,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 08

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.